Latest / Pharmacy Podcast Network / The Current Status of Biomarker Testing Coverage Legislation in the U.S. with Hilary Goeckner of the American Cancer Society Cancer Action N
Transcript
- 0:00Speaker 1: This episode is brought to you by Thermo Fisher Scientific.
- 0:03Speaker 1: Go from treat and wait to test and tailor. Use
- 0:06Speaker 1: genetic testing to research how to help patients get the
- 0:09Speaker 1: right medication dose for them at the right time the
- 0:12Speaker 1: first time. Pharmacogenomics or PGX has the potential to help
- 0:17Speaker 1: reduce healthcare costs and help protect lives. Physicians and pharmacists
- 0:21Speaker 1: can support the movement to integrate PGX into the standard
- 0:24Speaker 1: of care so patients can get tailored treatment with fewer
- 0:27Speaker 1: adverse reactions. Thermo Fisher Scientific has been helping to drive
- 0:31Speaker 1: PGX research for over a decade, and we continue to
- 0:34Speaker 1: invest and participate in collaborations to help make it accessible
- 0:38Speaker 1: and affordable. Explore pharmacogenomics at ThermoFisher dot com slash PGX education.
- 0:52Speaker 2: Thanks for listening to the Pharmacy Podcast Network.
- 1:10Speaker 3: In a world where one size fits all medications dominate
- 1:13Speaker 3: the pharmaceutical industry, precision medicine brings a ray of hope
- 1:17Speaker 3: for those seeking customized healthcare. Pharmacists have a unique opportunity
- 1:21Speaker 3: to help people in need of specialized testing to ensure
- 1:24Speaker 3: medications work is intended. Welcome to precision health in PGX,
- 1:29Speaker 3: where we unravel the wonders of precision medicine and its
- 1:32Speaker 3: potential to revolutionize the way we approach pharmacy care. Get
- 1:36Speaker 3: ready to uncover the secrets behind pharmacogenomics and how it's
- 1:40Speaker 3: transforming lives one genome aunt of time.
- 1:51Speaker 4: I am your host, doctor Becky Winslow, and you're listening
- 1:54Speaker 4: to the Precision Health and PGX podcasts. In case you're
- 1:58Speaker 4: wondering what happened to the Pharmacist podcasts, you're actually listening
- 2:02Speaker 4: to it right now, but only with a different name.
- 2:06Speaker 4: With a go to broaden our listenership outside of pharmacy
- 2:09Speaker 4: and pharmacists and broaden our content to include non pharmacodynemics
- 2:14Speaker 4: based precision health topics, my co host, doctor Banaserami, and
- 2:19Speaker 4: I decided to rebrand the podcasts so potential listeners would
- 2:22Speaker 4: and self exclude themselves from listening based on the podcast name.
- 2:27Speaker 5: Hey, and this is Bana's.
- 2:28Speaker 2: We're super excited about this new change, no different than
- 2:31Speaker 2: what we did on PJX for pharmacist podcasts. We'll continue
- 2:34Speaker 2: to explore all things pharmacogenomics related, including pharmacists role in PGX,
- 2:40Speaker 2: and our mission still includes educating and advocating for the
- 2:43Speaker 2: broader topic of precision medicine. We'll continue to accomplish this
- 2:47Speaker 2: mission through extensive interviews with highly qualified and well experienced
- 2:51Speaker 2: industry leaders.
- 2:53Speaker 4: Thanks Bona's So, today's special guests is Hillary Gettner. Hillary, welcome,
- 3:00Speaker 4: and please introduce yourself.
- 3:02Speaker 5: I thank you so much for having me. I'm Hillary G. Geckner.
- 3:05Speaker 6: I'm a director of State and Local Campaigns with the
- 3:08Speaker 6: American Cancer Society Cancer Action Network or acs CAN, or
- 3:13Speaker 6: the public policy affiliate of the American Cancer Society.
- 3:17Speaker 4: Thanks so much for introducing yourself. We're really fortunate to
- 3:20Speaker 4: have you as a guest today. As a pharmacogenomics access
- 3:24Speaker 4: and reimbursement specialist, I've been wanting to cover today's topic
- 3:28Speaker 4: on the podcast for a while now, and that is
- 3:31Speaker 4: biomarker testing's importance and the current status of biomarker testing
- 3:38Speaker 4: coverage and legislation in the United States today.
- 3:42Speaker 6: So just for our.
- 3:43Speaker 4: Audience's reference, just to get you up to speed in
- 3:46Speaker 4: case you're not aware. Prescribers often use biomarkers to help
- 3:51Speaker 4: determine the best treatment for a patient, but not all
- 3:54Speaker 4: communities are benefiting from the latest advancements in biomarker testing
- 3:59Speaker 4: and precision medicine due to payers differences in biomarker coverage
- 4:06Speaker 4: and reimbursement policies. Biomarker testing coverage and reimbursement is critical
- 4:13Speaker 4: for pharmacogenomics testing to become a standard of care in
- 4:18Speaker 4: both oncologic and non oncologic medication therapy management, and most
- 4:24Speaker 4: important for patients to realize pharmacogenomics testings benefits. Unfortunately, payers
- 4:32Speaker 4: have traditionally not voluntarily paid for clinically utih biomarker testing,
- 4:38Speaker 4: but fortunate for patients now, state legislators have begun working
- 4:43Speaker 4: to ensure more health plan payers cover this testing. So, Hillary,
- 4:50Speaker 4: could you please start off by introducing our audience to
- 4:54Speaker 4: the American Cancer Society Cancer Action Network and its mission
- 5:00Speaker 4: in general and specific to biomarker testing access. How does
- 5:05Speaker 4: acs can's mission align with the broader goals of improving
- 5:10Speaker 4: health care access and outcomes?
- 5:12Speaker 5: Sure?
- 5:13Speaker 6: So, As the affiliate public quality affiliate of the American
- 5:17Speaker 6: Cancer Society, acs CAN is working at the federal, state,
- 5:21Speaker 6: and local level to advance proven policies to end cancer
- 5:25Speaker 6: as we know it for everyone. So we're working on
- 5:28Speaker 6: cancer prevention policies like tobacco control, access to care, making
- 5:34Speaker 6: sure people have affordable insurance that covers the care that
- 5:38Speaker 6: they need, access to screenings, and then also that they're
- 5:42Speaker 6: able to get the cancer treatment that they.
- 5:44Speaker 5: Need, and supporting cancer research funding.
- 5:48Speaker 6: So there's a lot of really important policies and laws
- 5:54Speaker 6: that can help with addressing cancer. And so that's our mission,
- 5:59Speaker 6: that's our work, and we do this working with local, state,
- 6:04Speaker 6: and federal policymakers from all political backgrounds to do the
- 6:09Speaker 6: right thing for cancer patients and their families. And biomarket
- 6:13Speaker 6: testing is increasingly important in cancer care and in helping
- 6:17Speaker 6: cancer patients get the right treatment at the right time.
- 6:20Speaker 6: So this is a big priority for us to make
- 6:23Speaker 6: sure that all patients who can benefit from biomarcro testing
- 6:26Speaker 6: are able to get it.
- 6:29Speaker 4: That's a wonderful mission and needless to say, very much needed.
- 6:34Speaker 4: Can you tell us about your role in particular at
- 6:38Speaker 4: the American Cancer Society Cancer Action Network and you know
- 6:41Speaker 4: what inspired you to join the organization. I'm sure that
- 6:45Speaker 4: the mission that's evident, but could you elaborate on that
- 6:50Speaker 4: for us?
- 6:51Speaker 5: Sure?
- 6:52Speaker 6: So, like everyone, I have friends and family who've been
- 6:56Speaker 6: impacted by cancer and care very deeply about the mission
- 7:01Speaker 6: and making sure everyone has an equal opportunity to prevent, detect,
- 7:05Speaker 6: and survive cancer. And so acs CAN has a grassroots army,
- 7:12Speaker 6: if you will, volunteers across the country who are so
- 7:15Speaker 6: dedicated to this work and so impactful in speaking with
- 7:20Speaker 6: their lawmakers and advocating for the policies that will make
- 7:24Speaker 6: a difference for patients and their families.
- 7:28Speaker 2: We appreciate everything you guys are doing at the organization
- 7:31Speaker 2: yourself regarding this really awesome mission.
- 7:33Speaker 5: We appreciate that.
- 7:35Speaker 2: Can you tell us how you acs CAN is executing
- 7:39Speaker 2: its mission.
- 7:39Speaker 5: That's a lot to do, right, Yeah.
- 7:44Speaker 6: So I'm on a team that's focused primarily on state
- 7:48Speaker 6: legislative campaigns.
- 7:50Speaker 5: Federal officeholders and.
- 7:52Speaker 6: Policies often get a lot of the attention, but there's
- 7:55Speaker 6: so much important work that happens at the state level
- 7:58Speaker 6: and in state capitals. So we've got a government relations
- 8:02Speaker 6: director and a grassroots manager working in every single state
- 8:06Speaker 6: to lead campaigns to pass laws and policies that can
- 8:12Speaker 6: help with cancer prevention and access to care. And so
- 8:17Speaker 6: my focus is primarily on equitable access to biomarker testing.
- 8:21Speaker 6: I work on some other access to care issues as well,
- 8:24Speaker 6: fertility preservation, clinical trials, that sort of thing, But there's
- 8:28Speaker 6: a lot of enthusiasm and interest in our work around
- 8:31Speaker 6: biomarker testing.
- 8:33Speaker 5: Over the last two and a half three years, we've
- 8:35Speaker 5: been working to.
- 8:38Speaker 6: Introduce legislation to align insurance coverage policies across different health
- 8:44Speaker 6: plans to make sure that plans are covering the testing
- 8:49Speaker 6: that patients need and that doctors are ordering, because insurance
- 8:54Speaker 6: coverage is not keeping up with the latest advances in
- 8:58Speaker 6: biomarker testing, so there's really standard of care testing that
- 9:03Speaker 6: patients are missing out on, and there are a number
- 9:07Speaker 6: of challenges to ensuring that every patient who needs biomarker
- 9:11Speaker 6: testing can get it. But insurance coverage is a big
- 9:15Speaker 6: gap and an opportunity where state legislation can make a
- 9:20Speaker 6: big change. So the legislation that we're working on requires
- 9:24Speaker 6: coverage of biomarker testing for diagnosis, treatment, appropriate management, and
- 9:30Speaker 6: ongoing monitoring of a disease or condition. So this isn't
- 9:34Speaker 6: specific to cancer, if and only if that testing is
- 9:38Speaker 6: supported by certain evidence that's defined in the bill, so
- 9:42Speaker 6: that's FDA approved or clear tests, labeled indications on FDA
- 9:47Speaker 6: approved drugs, warnings and precautions on FDA approved drugs, So
- 9:51Speaker 6: pharmacogenomic testing very much falls under this biomarker testing legislation,
- 9:58Speaker 6: CMS coverage determination local coverage determinations for medicare contractors, and
- 10:03Speaker 6: then also nationally recognize clinical practice guidelines that providers rely on,
- 10:08Speaker 6: like those from NCCN.
- 10:10Speaker 5: So the idea is that these laws are.
- 10:12Speaker 6: Not set in time, but they will follow the evidence
- 10:16Speaker 6: and cover testing when it's proven and necessary to guide
- 10:20Speaker 6: patient treatment decisions.
- 10:23Speaker 2: So, going back a little, why why are the plans
- 10:28Speaker 2: not following the guidelines like, let's say, such as NCCN
- 10:31Speaker 2: guidelines to begin with, and why is there that gap?
- 10:34Speaker 5: To start off? Like it it makes sense everything you're.
- 10:37Speaker 2: Saying so doesn't make sense. Why the gap is there?
- 10:40Speaker 2: So if you can kind of explain why are we here?
- 10:44Speaker 5: Sure?
- 10:45Speaker 6: So, I can't speak for insurers and how they to
- 10:49Speaker 6: these decisions, but the unfortunate reality is that they're not
- 10:53Speaker 6: keeping up with the guidelines. I will say some papers
- 10:58Speaker 6: have analyzed plans and looked and they overwhelmingly refer to
- 11:02Speaker 6: NCCN guidelines. They say, we consider NCCN guidelines. One paper
- 11:08Speaker 6: I'm thinking of ninety one percent consultant or referenced NCCN guidelines,
- 11:13Speaker 6: but seventy one percent of those plans we're more restrictive
- 11:16Speaker 6: than the guidelines. So it doesn't matter to the patient
- 11:22Speaker 6: or the provider if you're considering them if you're not
- 11:24Speaker 6: following because oncology providers overwhelmingly rely on NCCN guidelines to
- 11:31Speaker 6: make sure that their patients are benefiting from the latest
- 11:34Speaker 6: science and staying up to date with the care that
- 11:38Speaker 6: patients need.
- 11:39Speaker 5: So do you have.
- 11:40Speaker 2: Any ideas of potentially what their thought processes. I know
- 11:45Speaker 2: you're not in their brains and you don't know, but
- 11:48Speaker 2: just doing this for a while and being in that space,
- 11:51Speaker 2: do you have any idea what potential reasons there could be.
- 11:55Speaker 6: The concern we always hear from insurers is about cost
- 12:00Speaker 6: and the cost of testing, so I would venture that
- 12:07Speaker 6: that might factor into their thinking. However, a number of
- 12:12Speaker 6: studies have shown that biomarker testing and pharmacogenomic testing especially
- 12:16Speaker 6: can lead to cost savings and cost avoidance. The challenges
- 12:20Speaker 6: that those savings are sometimes over a couple of years
- 12:23Speaker 6: or even a longer period of time, and particularly for
- 12:26Speaker 6: patients in active cancer treatment, they might be changing between
- 12:30Speaker 6: different insurance plans, either because they have to leave a job,
- 12:34Speaker 6: or they shift to a Medicaid plan, or they move
- 12:37Speaker 6: or whatever.
- 12:39Speaker 5: So sometimes it can be.
- 12:41Speaker 6: Hard for payers to voluntarily cover that testing knowing that
- 12:46Speaker 6: they might not see the benefit. However, with legislation like this,
- 12:51Speaker 6: when the plans are following the same rules, you know,
- 12:53Speaker 6: some of those costs and benefits are spread around the
- 12:56Speaker 6: plans because many plans right now are covering much of
- 12:59Speaker 6: this testing for many of the patients who need it.
- 13:03Speaker 6: And what the goal with this legislation is to level
- 13:06Speaker 6: the playing field and have all the plans follow the
- 13:09Speaker 6: same rules so that you can have some consistency and
- 13:13Speaker 6: equitable access across different plans.
- 13:16Speaker 4: I'm glad you brought that up. I'm glad you brought
- 13:20Speaker 4: that up, because you're exactly right. Someone's ensured should not
- 13:24Speaker 4: be one of their social determinants of health, you know,
- 13:28Speaker 4: especially when it comes to cancer care.
- 13:31Speaker 6: Yeah, and you know, we see really significant disparities and
- 13:35Speaker 6: inequities in cancer outcomes already.
- 13:39Speaker 5: You know, when.
- 13:39Speaker 6: Cancers are diagnosed, how long people survive, what kind of
- 13:42Speaker 6: care they're getting by race, income, insurance, by geography, and
- 13:49Speaker 6: as biomarker testing becomes more important in cancer care and
- 13:52Speaker 6: as treatments become more precise. We could see those disparities
- 13:56Speaker 6: and outcomes and survival increase if the only patients getting
- 14:01Speaker 6: biomarker testing have the means to pay out a pocket
- 14:04Speaker 6: or going to an academic medical center, or have the
- 14:07Speaker 6: right insurance. And so policy solutions like this are really
- 14:12Speaker 6: important to advance equitable access.
- 14:17Speaker 4: I agree absolutely based on my research, Hillary, I was
- 14:20Speaker 4: certain that you would name ACS can increase in the
- 14:25Speaker 4: number of states for which their legislators require biomarker testing
- 14:29Speaker 4: coverage for all state regulated plans as a key legislative victory.
- 14:34Speaker 4: Or maybe we haven't even gotten to that question. What
- 14:37Speaker 4: are your legislative victories and can you name the states
- 14:40Speaker 4: for us? Maybe just throw out a few names. I
- 14:43Speaker 4: know there's quite a list now of states that the
- 14:47Speaker 4: laws do require coverage. Maybe just share a few of
- 14:51Speaker 4: those and we can refer our audience to a longer list.
- 14:55Speaker 5: Sure.
- 14:55Speaker 6: So, we've worked with lawmakers across the country to advance
- 14:59Speaker 6: legislation to to expand insurance coverage of proven and necessary testing.
- 15:04Speaker 6: So similar laws have been passed in twenty states to date.
- 15:08Speaker 6: This is really across the gamut geographically politically. California, Texas, Georgia,
- 15:16Speaker 6: New York, Illinois, Rhode Island. So big states, small states,
- 15:21Speaker 6: Red states, Blue states, huge interests from lawmakers, and a
- 15:24Speaker 6: lot of success in a really short period of time.
- 15:27Speaker 5: And so, as I.
- 15:29Speaker 6: Touched on, this legislation requires coverage of biomarker testing, but
- 15:34Speaker 6: not just anything that calls itself biomarker testing. They're very
- 15:39Speaker 6: clear guardrails limiting both the circumstances for testing to diagnose
- 15:44Speaker 6: this treatment, management and monitoring of a disease or condition
- 15:48Speaker 6: if and only if that testing is supported by one
- 15:51Speaker 6: of the sources of evidence defined in the law, and
- 15:54Speaker 6: that's typically FDA approved and clear tests labeled indications and
- 15:58Speaker 6: warnings on FDA with drug labels, uh medicare, coverage determinations
- 16:03Speaker 6: both national and local and nationally recognized clinical practice guidelines
- 16:07Speaker 6: like NCCNCPICK and others.
- 16:10Speaker 4: Okay, and that's a and I think we should maybe
- 16:14Speaker 4: pause here also and say that you know, biomarker is
- 16:17Speaker 4: a very general term. Biomarkers are not just genetics related.
- 16:23Speaker 4: So although we talk a lot about genetics, can you
- 16:27Speaker 4: maybe expand for our audience on the term biomarker and
- 16:32Speaker 4: how inclusive videos And like you said, some could use
- 16:39Speaker 4: the term biomarker when maybe it's not appropriate.
- 16:44Speaker 6: Yes, yeah, so biomarker is something that can be measured
- 16:48Speaker 6: in your body. There are are many many things that
- 16:50Speaker 6: can fall fairly under the term biomarker. However, in cancer care,
- 16:56Speaker 6: we're typically talking about genetications protein expression. This is both
- 17:04Speaker 6: inherited genes and very often somatic or acquired mutations. And importantly,
- 17:14Speaker 6: this is where the guardrails and the legislation make a
- 17:16Speaker 6: big difference. This is not intended to cover testing for
- 17:21Speaker 6: screening purposes, so we're not talking about screening the general
- 17:25Speaker 6: population looking for cases of disease where there's no signs
- 17:30Speaker 6: or symptoms. But this is really important diagnostic testing that
- 17:33Speaker 6: allows doctors to subtype someone's cancer. So it's not just
- 17:38Speaker 6: you have breast cancer, you have lung cancer. We're going
- 17:41Speaker 6: to do trial and error on all these drugs that
- 17:43Speaker 6: might work, might not, see how it goes. But understanding, okay,
- 17:48Speaker 6: yes you have non small cell lung cancer, but you
- 17:50Speaker 6: have a KRS positive or EGFR mutation. Biomarkers are usually
- 17:56Speaker 6: known by three or four letters and or numbers, and
- 18:00Speaker 6: so some of these are inherited from mom and dad,
- 18:02Speaker 6: but most often, many of the markers we're talking about
- 18:06Speaker 6: are acquired over your lifetime, so it's not something that
- 18:10Speaker 6: you had at birth, and they're they're causing that cancer
- 18:13Speaker 6: to grow. And so the targeted treatments go after that
- 18:18Speaker 6: mutation and can effectively slow down the cancer and often
- 18:22Speaker 6: have fewer side effects because they're not as kind of
- 18:26Speaker 6: broad as traditional chemotherapy radiation that go after all fast
- 18:31Speaker 6: growing cells in your body.
- 18:33Speaker 4: I'm glad you made that are differentiated between semitic and
- 18:38Speaker 4: inherited for our audience purposes, because that is an important distinction.
- 18:44Speaker 4: And also the fact that you're not trying to get
- 18:49Speaker 4: coverage for screening tests because you know, in my experience,
- 18:54Speaker 4: payers just like you said, they want diagnostic not screening tests.
- 19:03Speaker 4: They want to pay for those versus screening, and again
- 19:06Speaker 4: because they want to realize the return on their investment
- 19:11Speaker 4: into that test over the time that the patient is
- 19:15Speaker 4: a beneficiary in their plan. And although medicure has typically
- 19:20Speaker 4: a longer a patient is in the plan longer, you know,
- 19:24Speaker 4: eighteen months for like employer sponsored plans is my understanding,
- 19:30Speaker 4: that's the average span for a beneficiary you know, on
- 19:34Speaker 4: a commercial plan.
- 19:36Speaker 6: So you know, you know, screening tests are very important,
- 19:40Speaker 6: and we also support work to advance access to you know,
- 19:45Speaker 6: guideline indicated screening.
- 19:46Speaker 5: Tests as well.
- 19:48Speaker 6: It's just kind of a separate category of work, and
- 19:52Speaker 6: we don't you want to go too big with with
- 19:56Speaker 6: what this one piece of legislation.
- 19:58Speaker 5: Is trying to accomplish.
- 19:59Speaker 6: So, like you know, multi cancer early detection tests would
- 20:04Speaker 6: be considered a biomarker test, but the purposes of that
- 20:08Speaker 6: type of testing would be a screening test, so looking
- 20:11Speaker 6: at general population or what have you to look for
- 20:15Speaker 6: cases of cancer where there are no signs or symptoms.
- 20:18Speaker 6: So that's separate from a diagnostic test that someone has
- 20:22Speaker 6: cancer or suspective cancer or other condition, and we're trying
- 20:25Speaker 6: to better understand that diagnosis and inform the treatment. And
- 20:31Speaker 6: you know, on the cost front, often biomarker testing can
- 20:35Speaker 6: help patients avoid unnecessary treatments that are often really expensive
- 20:41Speaker 6: and sometimes avoid overtreatment. So some patients won't benefit from
- 20:45Speaker 6: certain treatments or will have a much less aggressive disease
- 20:49Speaker 6: and will have the information to decide, I don't want
- 20:52Speaker 6: to overtreat this, and you know, have some treatment that's
- 20:56Speaker 6: just going to make me miserable and maybe won't give
- 20:58Speaker 6: me any clinical benefit. So it allows for more efficient
- 21:02Speaker 6: care delivery. Sometimes you know, it identifies patients are a
- 21:05Speaker 6: really good fit for really expensive treatment, but that's not
- 21:08Speaker 6: always the case.
- 21:09Speaker 4: Yes, and you know what I hear you describing is
- 21:12Speaker 4: clinical utility, and as research comes out, clinical utility research
- 21:18Speaker 4: comes out, that's what's going to help push payers, you know,
- 21:23Speaker 4: to see the value. I mean, you know, we're not
- 21:25Speaker 4: here to try to beat up payers today. I work
- 21:28Speaker 4: with payers. You know, their argument is valid. They want
- 21:32Speaker 4: to see returnal on their investment, and they want to
- 21:34Speaker 4: see real data, you know, to support that making that decision. So,
- 21:39Speaker 4: you know, just to make clear that you know, we
- 21:42Speaker 4: understand their perspective. We're just trying to do what we
- 21:45Speaker 4: can to make sure that our patients get taken care of.
- 21:49Speaker 5: So I have a follow up question if that's okay? Sure, sure, Yeah.
- 21:53Speaker 5: So here's a really one.
- 21:55Speaker 2: Offul Maybe it's already done or maybe this is a
- 21:57Speaker 2: dumb question, but is there room for collaboration or conversations
- 22:02Speaker 2: to be had with pharmaceutical companies ahead of when they're
- 22:06Speaker 2: you know, when you're developing a drug that suited for
- 22:09Speaker 2: some type of treatment that would require some biomarkers that
- 22:15Speaker 2: can be mentioned that could kind of potentially does that
- 22:18Speaker 2: make sense what I'm trying to say, like, unless they're
- 22:21Speaker 2: already in the packages of some of those but yeah,
- 22:24Speaker 2: still at.
- 22:25Speaker 6: My understanding is that a lot of targeted treatments are
- 22:29Speaker 6: getting FDA approval at the same time as.
- 22:31Speaker 5: A companion diagnostic. Yes, so the.
- 22:35Speaker 6: Labeled indications on FDA approved labels kind of gets at
- 22:38Speaker 6: that companion diagnostic and so often.
- 22:40Speaker 5: They receive FDA approval at the same time.
- 22:43Speaker 6: Yeah, sure, So, yeah, I think the biomarker testing is
- 22:50Speaker 6: increasingly important for accessing those newer treatments, but also biomarker
- 22:55Speaker 6: testing is really important for accessing clinical trials. Increasingly trials
- 23:02Speaker 6: are recruiting patients based on their biomarkers.
- 23:08Speaker 5: So rather than you know, this is a.
- 23:11Speaker 6: Lung cancer trial, and this is a prostate cancer trial,
- 23:13Speaker 6: and this is a breast cancer trial, you know, it's
- 23:16Speaker 6: this is a trial for people with an ROS one mutation.
- 23:22Speaker 6: And it doesn't matter where in your body we found
- 23:24Speaker 6: the cancer. Uh, you know, we are investigating. We think
- 23:28Speaker 6: this drug was treatment will be effective for this type
- 23:32Speaker 6: of tumor wherever it occurred.
- 23:35Speaker 4: Right, Yeah, absolutely, I mean because companion diagnostics are very important.
- 23:43Speaker 4: I mean, we're having an episode on breast cancer. You know,
- 23:48Speaker 4: the treatments for breast cancer an example of where companion
- 23:52Speaker 4: diagnostics are available before the patient consumes the medication to
- 23:59Speaker 4: make sure that they're making the medication that's going to
- 24:01Speaker 4: work for their type of breast cancer.
- 24:04Speaker 5: Exactly.
- 24:05Speaker 4: So absolutely good question. Bana's good question. Yeah, So back
- 24:12Speaker 4: to the state coverage. Can you elaborate for us on
- 24:18Speaker 4: how state laws differ as far as biomarker coverage goes.
- 24:24Speaker 6: Sure, So, generally speaking, most of these state laws are
- 24:28Speaker 6: very similar.
- 24:29Speaker 5: They'll look a little bit.
- 24:31Speaker 6: Different state to states to kind of each state has
- 24:34Speaker 6: their own style and they're fitting it into existing statutes,
- 24:37Speaker 6: but largely they have very similar language on the definitions,
- 24:42Speaker 6: on the circumstances when testing needs to be covered, and
- 24:45Speaker 6: on the sources of evidence that testing needs to meet.
- 24:52Speaker 6: But of those twenty states, fifteen currently apply to both
- 24:57Speaker 6: state regulated private plans, so large employer sponsored plans are
- 25:03Speaker 6: not subject to any state laws. This isn't unique to
- 25:06Speaker 6: biomarket testing, but they are only impacted by federal laws.
- 25:11Speaker 6: But individual marketplace plans small employer sponsored plans things like
- 25:16Speaker 6: that are subject to state laws, and then state Medicaid
- 25:20Speaker 6: programs vary significantly state to state. So fifteen of those
- 25:24Speaker 6: twenty states apply to the whole state regulated market. The
- 25:30Speaker 6: other five are slightly more piecemeal, and this is done
- 25:34Speaker 6: for either procedural or political reasons. But we're working to
- 25:37Speaker 6: continue to address the rest of the market. So Connecticut
- 25:41Speaker 6: and Florida looked specifically at medicaid and state employee health plan. Arkansas, Louisiana,
- 25:47Speaker 6: and Colorado past plans that apply.
- 25:50Speaker 5: To the private market.
- 25:52Speaker 6: So we're continuing work in those states to get the
- 25:55Speaker 6: missing piece.
- 25:56Speaker 5: Of the puzzle, if you will.
- 25:59Speaker 4: And that's a great way to differentiate the plans and
- 26:02Speaker 4: people need to, you know, I found that there's a
- 26:07Speaker 4: lack of understanding in the US of the complex US
- 26:13Speaker 4: healthcare payer system. There are community plans, there's state plans,
- 26:19Speaker 4: there's commercial plans, there're exchange plans. So many different plans
- 26:24Speaker 4: and they can have different guidelines. It can all be
- 26:31Speaker 4: called X y Z healthcare coverage. But each individual in
- 26:37Speaker 4: the plan, you know, within a certain group, is going
- 26:41Speaker 4: to have possibly different coverage based on the group therein
- 26:45Speaker 4: And I think there's really maybe not an appreciation for
- 26:50Speaker 4: how complex the healthcare coverage. I don't know if system
- 26:59Speaker 4: or marketplace or landscape landscape is the right one.
- 27:04Speaker 5: Yes, it's very very messy, very complicated.
- 27:07Speaker 4: Yes, yeah, So thanks for pointing that out to our audience.
- 27:13Speaker 4: So what are you seeing in other states? How do
- 27:15Speaker 4: you see the landscape of biomarker testing legislation involving in
- 27:21Speaker 4: the next few years? You know, like, where do we
- 27:23Speaker 4: go from here?
- 27:24Speaker 5: Sure?
- 27:25Speaker 4: What's it look like?
- 27:26Speaker 6: So we've seen legislative victories in those twenty states I've mentioned,
- 27:32Speaker 6: Legislation has been introduced in about ten additional states already
- 27:36Speaker 6: didn't get all the way through the process yet, though
- 27:40Speaker 6: New Jersey, Massachusetts, and Ohio are still working for this
- 27:44Speaker 6: year and have bills that.
- 27:46Speaker 5: Are active and could pass before the end of the year.
- 27:49Speaker 5: That we are running out of time.
- 27:51Speaker 6: Typically state legislative sessions happen in the first half of
- 27:55Speaker 6: the year, so we'll see a lot of activity early
- 27:57Speaker 6: in twenty twenty five, and we're continuing to work to
- 28:02Speaker 6: advance this legislation across the country. So hopefully we'll have
- 28:06Speaker 6: a much bigger number than twenty this time next year.
- 28:11Speaker 4: Let's hope. So I'd like to have you back in
- 28:13Speaker 4: a year or so that we can say sure, we
- 28:16Speaker 4: can say you guys did it right.
- 28:19Speaker 2: Yeah, these are exciting achievements and I appreciate all patient
- 28:23Speaker 2: stories can also be truly moving the needle when it
- 28:26Speaker 2: comes to building support for a clinical utile healthcare products
- 28:30Speaker 2: and services. So can you share some success stories where
- 28:35Speaker 2: buymorket testing really significantly impact a patient treatment outcome.
- 28:40Speaker 5: Yeah. So, patient stories are so important.
- 28:42Speaker 6: To all the work we do, particularly with this issue,
- 28:46Speaker 6: in kind of making it kind of meaningful to lawmakers
- 28:52Speaker 6: who often don't have necessarily a background in healthcare or science,
- 28:58Speaker 6: and individual stories of a patient who you know, got
- 29:03Speaker 6: on the right treatment after being told they had you know,
- 29:05Speaker 6: three to six months to live and they're doing great
- 29:08Speaker 6: six or seven years later.
- 29:10Speaker 5: That is so so.
- 29:11Speaker 6: Powerful and moving to lawmakers and makes it much easier
- 29:16Speaker 6: for them to stand up to the opposition on a
- 29:19Speaker 6: policy like this and vote to get patients the access
- 29:25Speaker 6: that they need. So patient stories are hugely helpful. We
- 29:29Speaker 6: also like to feature provider stories yea from you know, doctors, nurses, pharmacists,
- 29:36Speaker 6: social workers who could talk about the experiences and what
- 29:39Speaker 6: they see every day and the challenges they're up against
- 29:42Speaker 6: with you know, limitations in coverage policies, you know, not
- 29:46Speaker 6: following the science and what it means for their patients.
- 29:49Speaker 6: So we make it easy for people to get involved
- 29:53Speaker 6: and love to feature those stories. We have a whole
- 29:55Speaker 6: bunch of patient and provider stories that will have a
- 29:59Speaker 6: link in the notes to lots of two and three
- 30:03Speaker 6: minute videos we've.
- 30:04Speaker 5: Created to love that. Thank you illustrate this issue.
- 30:07Speaker 4: For people awesome. And I think benas and I'm speaking
- 30:11Speaker 4: for Bena's but I think we can both say. You know,
- 30:14Speaker 4: as pharmacists, you can agree, you can disagree with you.
- 30:20Speaker 5: I love it.
- 30:23Speaker 4: I know from my experience working as a pharmacist in
- 30:26Speaker 4: direct patient care, you know, hearing patient stories are what
- 30:31Speaker 4: really because we were right there on the front lines
- 30:35Speaker 4: and going to bat for those patients and fighting for
- 30:38Speaker 4: those patients to get the correct medication that they needed.
- 30:42Speaker 4: And really, I don't know about Bna's I won't speak
- 30:47Speaker 4: on this apartment and I think alike, but it really
- 30:52Speaker 4: inspired me to try to work more on a population
- 30:56Speaker 4: health level to try to get patients the treatment that
- 31:02Speaker 4: was the best for them. You know, the patient stories
- 31:09Speaker 4: are absolutely they are very impactful, so I'm glad they'll
- 31:14Speaker 4: have to share those.
- 31:16Speaker 5: Yeah.
- 31:16Speaker 4: Absolutely so. An very important objective for this episode, Hillary,
- 31:23Speaker 4: and you know we would be remiss not to do
- 31:26Speaker 4: this is to empower our listeners to get involved in
- 31:31Speaker 4: biomarker testing coverage advocacy. You know, we want them to
- 31:35Speaker 4: walk away today not only being maybe better educated about
- 31:41Speaker 4: biomarker testing in the current landscape for coverage, but you know,
- 31:46Speaker 4: we want to inspire them to get active, get out
- 31:50Speaker 4: there and help. So how can listeners get involved in
- 31:54Speaker 4: advocating for this testing coverage? And you know, I'm sure
- 31:58Speaker 4: ACS can offer resources to support to support individuals that
- 32:03Speaker 4: want to contribute to the cause.
- 32:05Speaker 5: Yeah, absolutely so.
- 32:06Speaker 6: I would encourage everyone to visit fight cancer dot org.
- 32:11Speaker 6: You can click on your state. There's a little drop
- 32:13Speaker 6: down menu and get connected with our staff and volunteers
- 32:19Speaker 6: in your state to get involved. We work on lots
- 32:22Speaker 6: of important cancer policy issues. Biomarket testing is a hot
- 32:26Speaker 6: topic and a whole bunch of states right now, so
- 32:29Speaker 6: we'd love to get connected with folks. And we host
- 32:34Speaker 6: a day at the capitol in every state legislature each
- 32:39Speaker 6: year and have lots of other opportunities to get involved.
- 32:42Speaker 5: So we'll let you know when there's a hearing.
- 32:44Speaker 6: Coming up, if we need a pharmacist or a doctor
- 32:47Speaker 6: to come talk about this issue and talk about what
- 32:50Speaker 6: it means to patients, or someone to speak to the
- 32:53Speaker 6: local media, or you know, we have easy action alerts
- 32:57Speaker 6: to contact your state lawmakers. So encourage everyone to visit
- 33:02Speaker 6: fight cancer dot org and get involved and get connected
- 33:06Speaker 6: with us.
- 33:06Speaker 5: We would love to work with you.
- 33:08Speaker 2: Yeah, as you were saying that, I went to the
- 33:10Speaker 2: website and on the very far right top it says
- 33:13Speaker 2: my state is so easy. You just put in your
- 33:16Speaker 2: state in pops up, so that that's great. I appreciate
- 33:18Speaker 2: you sharing that.
- 33:19Speaker 4: Yeah, yeah, making it easy is great. So thanks again. Hillary.
- 33:26Speaker 4: You know, we could talk about this all day. We
- 33:28Speaker 4: could make several episodes on this topic, elaborate on you know,
- 33:32Speaker 4: the individual segments that we focused on, but we we've
- 33:36Speaker 4: got to wrap up for today. So could you please
- 33:38Speaker 4: let our listeners know how they can reach out to
- 33:42Speaker 4: you if they have questions or want more information. You know,
- 33:45Speaker 4: what's your preferred method of communication?
- 33:48Speaker 6: Sure, folks are welcome to email me. It's Hillary dot
- 33:51Speaker 6: g e E at cancer dot org. One Alan Hillary
- 33:56Speaker 6: or reach out through the ACSCN website and we'll get
- 34:00Speaker 6: in touch with you.
- 34:02Speaker 4: All right, So again, thank you Hillary, and thank you
- 34:07Speaker 4: audience for tuning in. Without our faithful listeners, we wouldn't
- 34:11Speaker 4: have such a successful podcast and for that we're grateful
- 34:15Speaker 4: for you.
- 34:15Speaker 5: Guys.
- 34:16Speaker 2: Yeah, we do a lot of pgxing on here on
- 34:18Speaker 2: precision Health and PGX podcast, PGX science and clinical Application
- 34:22Speaker 2: in business and we hope you learned something today. As always,
- 34:25Speaker 2: you can visit us on PGX four the number four
- 34:28Speaker 2: RX dot com to listen to all our episodes. We
- 34:31Speaker 2: love to hear from you, So what can we teach you?
- 34:34Speaker 2: Drop us a message on LinkedIn and let us know
- 34:37Speaker 2: and please leave usten to a five star review on Apple
- 34:40Speaker 2: Podcasts or Spotify or wherever you prefer to listen to
- 34:43Speaker 2: your podcasts. So until next time, here's to moving the
- 34:46Speaker 2: trial and error.
- 34:47Speaker 5: From usine hm s